Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesAllergy/Clinical Immunologymarylandphysicianscarempc acute HAE coverage Prior…
    Ask Trek AI about this page
    CurrentmarylandphysicianscarempcPolicy RX.PA.001.MPC

    Acute Hereditary Angioedema Products: Berinert, Kalbitor, and Ruconest

    Customize your policy alerts

    Sign up for marylandphysicianscarempc Policy RX.PA.001.MPC alerts

    Get alerted when Policy RX.PA.001.MPC changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines prior authorization, coverage criteria, and renewal requirements for Berinert, Kalbitor, and Ruconest for treatment of acute hereditary angioedema (HAE) attacks for Maryland Physicians Care members and providers.

    Policy Summary
    Payermarylandphysicianscarempc
    PolicyAcute Hereditary Angioedema Products: Berinert, Kalbitor, and Ruconest
    Policy CodePolicy RX.PA.001.MPC
    Change TypeRoutine review — no material changes
    Effective Date
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization: initial requests must meet all listed criteria and are limited to one fill; reauthorizations may be extended annually with prescriber documentation of improvement.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3products covered
    1 fillinitial authorization fill limit
    up to 1 yearreauthorization interval
    3HCPCS codes listed

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Coverage Criteria for Acute HAE Products

    Initial Authorization

    Covered when ALL of the following are met:

    Initial Authorization criteria: 1) Prescription for treatment of acute HAE attacks.

    Prescriber requirement

    • Must be prescribed by or under the direction of an HAE specialist (defined as an allergist/immunologist who demonstrates clinical expertise in HAE through research, publication, referrals/consults).

    Diagnostic confirmation

    • Diagnosis of HAE confirmed by ALL of the following laboratory values on two separate instances (copy of laboratory reports required; must include reference ranges): low C4 complement level.
    • Normal C1q complement component level (C1q not required for patients <18 years or whose symptoms began before age 18).
    • AND either of the following

      • Low C1 esterase inhibitor antigenic level.
      • Low C1 esterase inhibitor functional level.
    Prior exposure and documentation: Must have received at least one dose of the requested product for an acute HAE attack in the past with chart documentation indicating patient response and ability to tolerate the medication (copy of chart documentation required).

    Age requirements (product-specific)

    • Berinert: member is 2 years of age or older.
    • Kalbitor: member is 12 years of age or older.
    • Ruconest: member is 13 years of age or older.
    Dosing requirement: Prescribed dose must be within the manufacturer's dosing guidelines as listed in the FDA‑approved labeling (based on diagnosis, weight, etc.).

    Reauthorization

    Covered when ALL of the following are met:

    Reauthorization criteria: All prior authorization renewals are reviewed annually. Documentation from the prescriber that the member's condition has improved based upon the prescriber's assessment while on therapy is required.

    Authorizations may be extended at 1-year intervals.

    Members with prior approval or samples: Members who received prior approval from an insurer other than MPC or who have been receiving medication samples should be evaluated under Initial Authorization criteria; provider must document positive clinical response to therapy from baseline.

    Not covered / investigational uses

    Investigational/Not covered uses: Acute hereditary angioedema products are considered investigational or experimental for any other use and will not be covered.

    Any use of the listed acute hereditary angioedema (HAE) products outside of treatment for acute HAE attacks is considered investigational/experimental and is not covered.

    Billing and Coding

    HCPCS CodesHCPCS
    J0596Injection, C1 esterase inhibitor (recombinant), Ruconest, 10 units.
    J0597Injection, C1 esterase inhibitor (human), Berinert, 10 units.
    J1290Injection, ecallantide, 1 mg

    Provider Actions, Documentation, and Denial Triggers

    Prior Authorization

    Prior authorization required; initial limit 1 fill and annual reauthorization

    Prior authorization is required for Berinert, Kalbitor, and Ruconest; initial approvals must meet all listed initial authorization criteria and are limited to 1 fill. Reauthorizations are reviewed annually and may be extended at 1-year intervals with prescriber documentation of improvement.

    • Initial Authorization limited to 1 fill.
    • Reauthorization reviewed on an annual basis; may be extended at 1-year intervals.
    Step Therapy

    Dosing must follow FDA‑approved manufacturer labeling

    Prescribed dose must follow the manufacturer's dosing guidelines as listed in the FDA‑approved labeling (dose determined by diagnosis, weight, etc.).

    • Dose must be within manufacturer's dosing guidelines per FDA labeling.

    Background

    Hereditary angioedema (HAE) is a rare disorder characterized by recurrent swelling attacks caused by deficiency or dysfunction of C1 esterase inhibitor. This policy applies to acute HAE treatment products — Berinert (human C1 esterase inhibitor), Kalbitor (ecallantide), and Ruconest (recombinant C1 esterase inhibitor) — and defines prior authorization, coverage criteria, and renewal requirements for their use in treating acute attacks.

    Coverage is limited to members who meet diagnostic confirmation requirements and other criteria in the policy (for example, laboratory confirmation on two separate occasions, prescriber expertise, prior receipt of the requested product with documented response, and age-specific product indications).

    Definitions

    Hereditary Angioedema (HAE) — definition and common clinical features
    DefinitionA rare disorder characterized by recurrent attacks of swelling that may involve the peripheral extremities, abdomen, genitalia, face, oropharynx, or larynx due to low levels of endogenous or functional C1 inhibitor.
    Typical anatomic sitesPeripheral extremities, abdomen, genitalia, face, oropharynx, or larynx.
    Underlying defectLow levels or dysfunctional C1 esterase inhibitor (C1-INH).
    Products covered under policyBerinert (C1 esterase inhibitor, human); Kalbitor (ecallantide); Ruconest (C1 esterase inhibitor, recombinant).
    HAE specialist — required clinician qualifications
    DefinitionAn allergist/immunologist who demonstrates clinical expertise in HAE through research, publication, referrals/consults.
    Policy Summary
    Payermarylandphysicianscarempc
    PolicyAcute Hereditary Angioedema Products: Berinert, Kalbitor, and Ruconest
    Policy CodePolicy RX.PA.001.MPC
    Change TypeRoutine review — no material changes
    Effective Date
    Last ReviewApr 1, 2026
    Next Review DateApr 1, 2026
    Key ActionObtain prior authorization: initial requests must meet all listed criteria and are limited to one fill; reauthorizations may be extended annually with prescriber documentation of improvement.
    SourceLink
    On This Page
    Coverage Criteria for Acute HAE ProductsBilling and CodingProvider Actions, Documentation, and Denial TriggersBackgroundDefinitions
    Documentation Required

    Required documentation: labs, chart notes, and prescriber assessment

    Providers must submit objective laboratory confirmation and chart evidence: copies of lab reports (including reference ranges) showing required diagnostic labs on two separate occasions, and chart documentation of prior receipt of at least one dose with response and tolerability; for renewals, documentation from the prescriber that the member's condition has improved.

    • Copy of laboratory reports (must include reference ranges) documenting on two separate instances: low C4; normal C1q (not required if patient <18 or symptoms began <18); and either low C1 esterase inhibitor antigenic level OR low C1 esterase inhibitor functional level.
    • Chart documentation that the member received at least one prior dose of the requested product for an acute HAE attack with documented response and tolerability.
    • For reauthorization: prescriber documentation that the member's condition has improved while on therapy.
    • Members with prior approval from another insurer or receiving samples must be evaluated under Initial Authorization criteria with documentation of positive clinical response from baseline.
    Denial Risk

    Denial triggers and Medical Director referral for unmet criteria

    Requests will be denied or referred to a Medical Director when the established criteria are not met; note limits include an initial authorization of 1 fill and reauthorization of up to 1 year which may be denied if criteria are not satisfied.

    • Denial trigger: failure to meet all Initial Authorization criteria (including diagnostic labs, specialist prescriber, prior dose with documented response, age requirements, and appropriate dosing).
    • Non‑covered/investigational use: any use other than treatment of acute HAE attacks is excluded from coverage.
    • Requests not meeting criteria may be referred to a Medical Director for review as required by the plan and level of request.
    Role requirementPrescriptions must be written by or under the direction of an HAE specialist for coverage consideration.
    Evidence of expertiseDemonstrated clinical expertise via research, publication, or management of referrals/consults specific to HAE.